Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: A bedside-to-bench study

Stroke

Volumn 32, Issue 11, 2001, Pages 2665-2674

  Furuya, Kazuhide ^a   Takeda, Hidetaka ^a   Azhar, Salman ^a   McCarron, Richard M ^a,b   Chen, Yong ^a   Ruetzler, Christl A ^a   Wolcott, Karen M ^c   DeGraba, Thomas J ^a   Rothlein, Robert ^d   Hugli, Tony E ^e   Del Zoppo, Gregory J ^e   Hallenbeck, John M ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b Office of Research Regulatory Affairs   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Antibodies; Cell adhesion molecules; Cerebral ischemia; Clinical trials; Leukocytes; Rats

Indexed keywords

ANTIBODY; CD11B ANTIGEN; COMPLEMENT; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; MYELOPEROXIDASE; PADGEM PROTEIN; ALLOANTIBODY; COMPLEMENT 3A, DES ARG; COMPLEMENT 3A, DES-ARG-; COMPLEMENT COMPONENT C3A; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; PEROXIDASE; SELECTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; IMMUNE RESPONSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SENSITIZATION; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE; TREATMENT OUTCOME; ANIMAL; BODY WEIGHT; BRAIN; BRAIN CIRCULATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; ENZYMOLOGY; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LASER DOPPLER FLOWMETRY; LEUKOCYTE COUNT; METABOLISM; MOUSE; PATHOLOGY; RAT STRAIN;

ANIMAL; ANTIBODIES, MONOCLONAL; BODY WEIGHT; BRAIN; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR CIRCULATION; CLINICAL TRIALS; COMPLEMENT 3A; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; INTERCELLULAR ADHESION MOLECULE-1; ISOANTIBODIES; LASER-DOPPLER FLOWMETRY; LEUKOCYTE COUNT; MICE; PEROXIDASE; RATS; RATS, INBRED SHR; RATS, WISTAR; SELECTINS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0035164475     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/hs3211.098535     Document Type: Article

References (43)

1. Anti-adhesion molecule and nitric oxide protection strategies in ischemic stroke
2. Experimental antileukocyte interventions in cerebral ischemia
3. Inflammatory reactions at the blood-endothelial interface in acute stroke
4. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons
5. Polymorphonuclear leukocyte accumulation in brain regions with low blood flow during the early postischemic period
6. Influx of leukocytes and platelets in an evolving brain infarct (Wistar rat)
7. Monocyte adherence to human vascular endothelium
8. Selectins
9. Endothelial-leukocyte adhesion molecules
10. Monoclonal antibody to the ICAM-1 adhesion site reduces neurological damage in a rabbit cerebral embolism stroke model
11. Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats
12. Role of cell adhesion molecules in brain injury after transient middle cerebral artery occlusion in the rat
13. Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat
14. Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat
15. In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts
16. The Enlimomab Acute Stroke Trial: Final results (abstract and presentation) in 49th Annual Meeting of the American Academy of Neurology
17. Identification of monoclonal antibodies reactive with the rat homolog of ICAM-1, and evidence for a differential involvement of ICAM-1 in the adherence of resting versus activated lymphocytes to high endothelial cells
18. Intercellular adhesion molecule 1 (ICAM-I) expression and its role in neutrophil-induced ischemia-reperfusion injury in rat liver
19. ICAM-1 mediates leukocyte-endothelium adhesive interactions in the reversed passive Arthus reaction
20. A monoclonal antibody against ICAM-1 suppresses hepatic ischemia-repeffusion injury in rats
21. ICAM-1 affects reperfusion injury and graft function after cardiac transplantation
22. Evaluation of the role of intercellular adhesion molecule 1 in a rodent model of chronic venous hypertension
23. Treatment of focal cerebral ischemia with synthetic oligopeptide corresponding to lectin domain of selectin
24. BW619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage see comments
25. Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats
26. Polymorphonuclear leukocyte infiltration into cerebral focal ischemic tissue: Myeloperoxidase activity assay and histologic verification
27. Possible mechanism for in vitro complement activation in blood and plasma samples: Futhan/EDTA controls in vitro complement activation
28. Lectin binding by resting and reactive microglia
29. An improved staining method for rat microglial cells using the lectin from Griffonia simplicifolia (GSA I-B4)
30. P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion
31. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy
32. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?
33. Human immune response to multiple injections of murine monoclonal IgG
34. Safety, pharmacokinetics and biological activity of Enlimomab (anti-ICAM-1 antibody): An open-label, dose escalation study in patients hospitalized for acute stroke
35. Novel antibody drug products
36. Anti-ICAM-1 monoclonal antibody R6.5 (Enlimomab) promotes activation of neutrophils in whole blood
37. Complement and tumor necrosis factor-alpha contribute to Mac-1 (CD11b/CD18) up-regulation and systemic neutrophil activation during endotoxemia in vivo
38. Altered leukocyte immunophenotypes in septic shock: Studies of HLA-DR, CD11b, CD14, and IL-2R expression
39. Increased expression of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis
40. Leukocyte activation in the peripheral blood of patients with cirrhosis of the liver and SIRS: Correlation with serum interleukin-6 levels and organ dysfunction
41. Role of polymorphic Fc receptor Fc gammaRIIa in cytokine release and adverse effects of murine IgG1 anti-CD3/T cell receptor antibody (WT31)
42. Immunosuppression with monoclonal anti-T3 antibody (WT32) in renal transplantation